Filing Flows › Heron Therapeutics (HRTX) › Q3 2026 › vs Q3 2025
Heron Therapeutics (HRTX) Q3 2026 vs Q3 2025 (year over year)
Heron Therapeutics's revenue fell $3.0M (-8%) from $38.2M in Q3 2025 to $35.2M in Q3 2026. The biggest changes: CINVANTI −$4.0M (-17%); SUSTOL −$1.8M (-92%); Aponvie +$1.5M (+49%).
Heron Therapeutics, Q3 2026: revenue $35.2M (-8% year over year), operating margin -4.7%, net loss $5.0M, operating cash flow −$794K. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| CINVANTI | $20.0M | $24.0M | −$4.0M | -17% |
| ZYNRELEF | $10.6M | $9.3M | $1.3M | +14% |
| Aponvie | $4.5M | $3.0M | $1.5M | +49% |
| SUSTOL | $152K | $1.9M | −$1.8M | -92% |
| Revenue | $35.2M | $38.2M | −$3.0M | -8% |
| Net loss | $5.0M | $17.5M | −$12.5M | -71% |
| Costs & expenses | $40.3M | $55.7M | −$15.5M | -28% |
| Operating costs | $36.9M | $42.3M | −$5.4M | -13% |
| Interest & other, net | $3.3M | $13.4M | −$10.1M | -75% |
| Cost of revenue | $9.0M | $11.9M | −$3.0M | -25% |
| Research & development | $3.1M | $3.5M | −$371K | -11% |
| Sales & marketing | $12.5M | $12.9M | −$421K | -3% |
| General & admin | $12.3M | $14.0M | −$1.6M | -12% |
| Operating cash sources | $5.0M | $17.5M | −$12.5M | -71% |
| Depreciation & amortization | $391K | $615K | −$224K | -36% |
| Share-based compensation | $3.1M | $2.9M | $231K | +8% |
| Working capital & other | $738K | $15.4M | −$14.6M | -95% |
| Cash used in operations | $794K | −$1.3M | $2.1M | — |
| Net loss absorbed | $5.0M | $17.5M | −$12.5M | -71% |
Questions
How much did Heron Therapeutics's revenue grow year over year in Q3 2026?
Heron Therapeutics's revenue fell $3.0M (-8%) from $38.2M in Q3 2025 to $35.2M in Q3 2026.
What drove Heron Therapeutics's revenue change in Q3 2026?
CINVANTI −$4.0M (-17%); SUSTOL −$1.8M (-92%); Aponvie +$1.5M (+49%).